Home › Funds › ADAR1 Capital Management, LLC › CRNX

ADAR1 Capital Management, LLC position in CRNX

CRINETICS PHARMACEUTICALS IN

ADAR1 Capital Management, LLC reported holding 1,222,080 shares of CRNX (CRINETICS PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$45.7M, representing 2.53% of its reported portfolio and ranking #6 among its reported holdings. ADAR1 Capital Management, LLC has disclosed CRNX holdings in 9 of the last 9 reported quarters, going back to Q2 2024.

Latest position (Q2 2026)1.22M sh
Reported value held$45.73M
Portfolio Weight2.53%
First reportedQ2 2024
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ADAR1 Capital Management, LLC's CRNX position evolved

ADAR1 Capital Management, LLC first disclosed a stake in CRNX in Q2 2024 at 74,850 shares (US$3.4M). The position peaked in Q2 2026 at 1,222,080 shares, worth US$45.7M. Across 9 filings, ADAR1 Capital Management, LLC increased the stake 5 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 1,222,080 shares valued at US$45.7M — an increase of 82,749 shares quarter over quarter.. Notable position changes include a 40% trim in Q4 2024, a 368% increase in Q3 2025, a 268% increase in Q1 2026.

Quarter by quarter

QuarterSharesValueChange
Q2 2024 74.85K $3.35M New
Q3 2024 88.42K $4.52M Add
Q4 2024 53.12K $2.72M Reduce
Q1 2025 53.12K $1.78M Hold
Q2 2025 53.12K $1.53M Hold
Q3 2025 248.37K $10.34M Add
Q4 2025 309.37K $14.40M Add
Q1 2026 1.14M $41.38M Add
Q2 2026 1.22M $45.73M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CRNX and 13F data

CRNX (CRINETICS PHARMACEUTICALS IN) is a company whose sector is not yet classified in our data. 37 other funds we track also report a position in CRNX — the largest reported positions include Farallon Capital Management (US$336.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$336.4M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$241.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CRNX

All CRNX fund holders →

FAQ

How long has ADAR1 Capital Management, LLC held CRNX?

ADAR1 Capital Management, LLC has disclosed CRNX holdings in 9 of the last 9 reported quarters, going back to Q2 2024.

What is ADAR1 Capital Management, LLC's current position in CRNX?

As of Q2 2026, ADAR1 Capital Management, LLC holds 1.22M shares of CRNX (CRINETICS PHARMACEUTICALS IN), valued at $45.73M, representing 2.53% of its reported portfolio and ranking #6.

Has ADAR1 Capital Management, LLC been buying or selling CRNX?

In the latest 13F filing (Q2 2026), ADAR1 Capital Management, LLC increased its position in CRNX. The position peaked in Q2 2026 at 1.22M shares.

Which other funds hold CRNX?

Other major institutional holders of CRNX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., DRIEHAUS CAPITAL MANAGEMENT LLC, among 37 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.